Defining the Diagnostic Value of High-Pitch CCTA and Dynamic CT Perfusion in patients with prior PCI for the Diagnosis of Myocardial Ischemia as Defined by Invasive Flow and Pressure Indices - The PACIFIC-III trial

Defining the Diagnostic Value of High-Pitch CCTA and Dynamic CT Perfusion in patients with prior PCI for the Diagnosis of Myocardial Ischemia as Defined by Invasive Flow and Pressure Indices - The PACIFIC-III trial - The PACIFIC-III trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50843

Enrollment

140

Registered

2021-06-22

Start date

2021-11-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis Coronary artery disease

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - History of PCI for stable CAD - Referred for a diagnostic ICA. - Age above 35 years.

Exclusion criteria

Exclusion criteria: - History of severe COPD or chronic asthma - Pregnancy - Renal failure (eGFR

Design outcomes

Primary

Measure	Time frame
To assess the diagnostic performance in terms of sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and diagnostic accuracy of high-pitch CCTA and dynamic CTP for the diagnosis of significant CAD as defined by an FFR	—

Secondary

Measure	Time frame
(1) To compare the diagnostic capabilities of high pitch CCTA and dynamic CTP to detect significant CAD when defined by instantaneous wave-free ratio (iFR). (2) To investigate the potential of high-pitch CCTA to improve plaque characterization and as such diagnosis of ischemia - due to mounting evidence suggesting a relationship between adverse plaque characteristics and ischemia - and prognosis. (3) To evaluate the prognostic value of high-pitch CCTA and dynamic CTP.	—

Measure

Time frame

(1) To compare the diagnostic capabilities of high pitch CCTA and dynamic CTP to detect significant CAD when defined by instantaneous wave-free ratio (iFR). (2) To investigate the potential of high-pitch CCTA to improve plaque characterization and as such diagnosis of ischemia - due to mounting evidence suggesting a relationship between adverse plaque characteristics and ischemia - and prognosis. (3) To evaluate the prognostic value of high-pitch CCTA and dynamic CTP.

—

Countries

Netherlands

Outcome results